Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus Infection

Abstract

The described invention provides a method for treating a subject at risk for a lung injury derived from a severe virus infection. The steps of the method include (a) receiving a subcutaneous injection of a bone marrow stimulant to mobilize CD34+ cells into the peripheral blood; (b) harvesting CD34+ cells from the peripheral blood by apheresis; (c) selecting CD34+ cells by positive selection; (d) formulating a CLBS119 cell product by suspending the selected CD34+ cells in an isotonic solution with serum ranging from 5% to 40%, inclusive and human serum albumin ranging from 0.5%-10%, inclusive, to form a pharmaceutical composition; and (e) administering the cell product to the subject. The sterile pharmaceutical composition contains a therapeutic amount of a mobilized nonexpanded, isolated population of autologous mononuclear cells enriched for CD34+ cells with a purity ranging from 55% to 100%, inclusive, which further contains a subpopulation of potent CD34+/CXCR4+ cells. The mobilized nonexpanded, isolated population of autologous mononuclear cells enriched for CD34+ cells with a purity ranging from 55% to 100%, inclusive, which further contains a subpopulation of potent CD34+/CXCR4+ cells when tested in vitro after passage through an infusion catheter after acquisition: (i) has CXCR-4 mediated chemotactic activity and moves in response to SDF-1; (ii) can form hematopoietic colonies; and (iii) is at least 80% viable. According to some embodiments, the severe virus infection is caused by influenza or a human coronavirus.

Dependencies are inferred from the claim text.